Syndax Q4 Revuforj $44.2M (+38% QoQ); Niktimvo $56M; net loss $68M

Syndax Pharmaceuticals Inc

2025-FY EPS reported -$3.29 revenue$172,352,000

Total revenue $68.7M in Q4 and $172.4M in FY2025, driven by Revuforj and Niktimvo launches.
Revuforj net revenue $44.2M in Q4 (+38% vs Q3) and $124.8M in FY2025; ~1,150 prescriptions in Q4.
Niktimvo net revenue $56M in Q4 (+22% vs Q3) and $151.6M in FY2025; Syndax collaboration revenue $42.4M FY.
Net loss $68M (0.78/share) in Q4 and $285.4M ($3.29/share) for FY2025; cash $394.1M at year-end.
FY2026 opex guidance ~$400M ex-stock comp; expects profitability from cash, revenue, and interest income.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.